Form 4: Bausch + Lomb CEO's Performance Stock Unit Award Amended, Increasing Potential Share Vesting

Bausch + Lomb's CEO and Chairman, Brent L. Saunders, reported an amendment to his performance stock unit award, increasing the minimum number of shares eligible to vest to 900,000.

Summary

• Brent L. Saunders, CEO and Chairman of Bausch + Lomb Corp (BLCO), filed a Form 4 regarding an amendment to his performance stock unit (PSU) award.
• The amendment, effective July 21, 2025, modifies the "New Hire PSUs" originally granted on February 23, 2023, under the 2022 Omnibus Incentive Plan.
• Each PSU grants the right to receive one common share of Bausch + Lomb.
• The PSUs can be earned and vest between 120% and 330% of the target award.
• Vesting is contingent upon achieving specified share-price hurdle goals and a cumulative Adjusted EBITDA performance modifier goal, subject to continued employment through the Measurement End Date of February 23, 2029.
• Previously, Saunders reported beneficial ownership of 750,000 common shares (the target number) in a Form 3 filed on March 6, 2023.
• As a result of this amendment, Saunders is now reporting the acquisition of an additional 150,000 PSUs.
• This brings the total reported beneficial ownership to 900,000 common shares, representing the minimum number of shares eligible to vest on the Measurement End Date.

Sentiment

Score: 7

Explanation: The filing indicates an increase in the potential long-term equity compensation for the CEO, tied to performance metrics. This generally aligns management incentives with shareholder value, which is a positive. It's a routine compensation adjustment, not a major operational or financial announcement, hence a neutral-to-positive score.

Positives

• The amendment increases the potential share vesting for the CEO, aligning executive incentives with long-term company performance.
• The performance-based vesting conditions (share price hurdles and Adjusted EBITDA targets) indicate a focus on key financial and market metrics.

Risks

• Achievement of the full PSU award is subject to future share-price performance and Adjusted EBITDA targets, which are not guaranteed.
• The vesting is contingent on the CEO's continued employment through February 23, 2029.

Future Outlook

The future outlook for the CEO's compensation is tied to the achievement of specific share-price hurdle goals and a cumulative Adjusted EBITDA performance modifier goal by February 23, 2029. The potential vesting ranges from 120% to 330% of the target award, indicating a strong incentive for long-term value creation.

Industry Context

This filing reflects a common practice in corporate governance where executive compensation, particularly long-term incentives, is structured to align management interests with shareholder value creation through performance-based equity awards. The use of share price hurdles and Adjusted EBITDA targets are standard metrics in the pharmaceutical/medical device industry for executive compensation.

Comparison to Industry Standards

• The use of performance stock units (PSUs) with multi-year vesting periods and performance hurdles (share price and Adjusted EBITDA) is a standard practice for executive long-term incentive plans across the healthcare and pharmaceutical industries, similar to companies like Johnson & Johnson, Medtronic, or Abbott Laboratories.
• The structure aims to incentivize sustained financial performance and shareholder returns, aligning with best practices in corporate governance for large, publicly traded companies.
• The specific percentage ranges for vesting (120% to 330% of target) are within typical ranges for high-performance incentive plans designed to reward exceptional achievement.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact as CEO's long-term incentives are further aligned with shareholder value creation through performance-based equity.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Continued monitoring of Bausch + Lomb's share price performance and Adjusted EBITDA results towards the February 23, 2029, Measurement End Date.
• Future SEC filings (e.g., proxy statements, 10-K) will provide more details on the specific share price hurdles and Adjusted EBITDA targets.

Key Dates

Recommendation

This Form 4 filing details a routine amendment to an executive's performance-based equity award, increasing the potential shares tied to future company performance. While it aligns management incentives with shareholder interests, it does not present new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation disclosure.

Keywords

Bausch + Lomb, BLCO, Performance Stock Units, PSUs, Executive Compensation, Equity Award, CEO, Brent L. Saunders, SEC Form 4, Incentive Plan, Adjusted EBITDA, Share Price Hurdles